7 research outputs found
Structural characterization of antibody drug conjugate by a combination of intact, middle-up and bottom-up techniques using sheathless capillary electrophoresis â Tandem mass spectrometry as nanoESI infusion platform and separation method
Antibody-drug conjugates (ADCs) represent a fast growing class of biotherapeutic products. Their production leads to a distribution of species exhibiting different number of conjugated drugs overlaying the inherent com-plexity resulting from the monoclonal antibody format, such as glycoforms. ADCs require an additional level of characterization compared to first generation of biotherapeutics obtained through multiple analytical tech-niques for complete structure assessment. We report the development of complementary approaches imple-menting sheathless capillary electrophoresis-mass spectrometry (sheathless CE-MS) to characterize the differ-ent aspects defining the structure of brentuximab vedotin. Native MS using sheathless CE-MS instrument as a nanoESI infusion platform enabled accurate mass measurements and estimation of the average drug to anti-body ratio alongside to drug load distribution. Middle-up analysis performed after limited IdeS proteolysis allowed to study independently the light chain, Fab and F(abâ)2 subunits incorporating 1, 0 to 4 and 0 to 8 pay-loads respectively. Finally, a CZE-ESI-MS/MS methodology was developed in order to be compatible with hy-drophobic drug composing ADCs. From a single injection, complete sequence coverage could be achieved. Using the same dataset, glycosylation and drug-loaded peptides could be simultaneously identified revealing robust information regarding their respective localization and abundance. Drug-loaded peptide fragmentation mass spectra study demonstrated drug specific fragments reinforcing identification confidence, undescribed so far. Results reveal the method ability to characterize ADCs primary structure in a comprehensive manner while reducing tremendously the number of experiments required. Data generated showed that sheathless CZE-ESI-MS/MS characteristics position the methodology developed as a relevant alternative for comprehensive multi-level characterization of these complex biomolecule
NIST Interlaboratory Study on Glycosylation Analysis of Monoclonal Antibodies: Comparison of Results from Diverse Analytical Methods
Glycosylation is a topic of intense current interest in the
development of biopharmaceuticals because it is related
to drug safety and efficacy. This work describes results of
an interlaboratory study on the glycosylation of the Primary
Sample (PS) of NISTmAb, a monoclonal antibody
reference material. Seventy-six laboratories from industry,
university, research, government, and hospital sectors
in Europe, North America, Asia, and Australia submit-
Avenue, Silver Spring, Maryland 20993; 22Glycoscience Research Laboratory, Genos, Borongajska cesta 83h, 10 000 Zagreb, Croatia;
23Faculty of Pharmacy and Biochemistry, University of Zagreb, A. KovacË icÂŽ a 1, 10 000 Zagreb, Croatia; 24Department of Chemistry, Georgia
State University, 100 Piedmont Avenue, Atlanta, Georgia 30303; 25glyXera GmbH, Brenneckestrasse 20 * ZENIT / 39120 Magdeburg, Germany;
26Health Products and Foods Branch, Health Canada, AL 2201E, 251 Sir Frederick Banting Driveway, Ottawa, Ontario, K1A 0K9 Canada;
27Graduate School of Advanced Sciences of Matter, Hiroshima University, 1-3-1 Kagamiyama Higashi-Hiroshima 739â8530 Japan; 28ImmunoGen,
830 Winter Street, Waltham, Massachusetts 02451; 29Department of Medical Physiology, Jagiellonian University Medical College,
ul. Michalowskiego 12, 31â126 Krakow, Poland; 30Department of Pathology, Johns Hopkins University, 400 N. Broadway Street Baltimore,
Maryland 21287; 31Mass Spec Core Facility, KBI Biopharma, 1101 Hamlin Road Durham, North Carolina 27704; 32Division of Mass
Spectrometry, Korea Basic Science Institute, 162 YeonGuDanji-Ro, Ochang-eup, Cheongwon-gu, Cheongju Chungbuk, 363â883 Korea
(South); 33Advanced Therapy Products Research Division, Korea National Institute of Food and Drug Safety, 187 Osongsaengmyeong 2-ro
Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, 363â700, Korea (South); 34Center for Proteomics and Metabolomics, Leiden
University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands; 35Ludger Limited, Culham Science Centre, Abingdon,
Oxfordshire, OX14 3EB, United Kingdom; 36Biomolecular Discovery and Design Research Centre and ARC Centre of Excellence for Nanoscale
BioPhotonics (CNBP), Macquarie University, North Ryde, Australia; 37Proteomics, Central European Institute for Technology, Masaryk
University, Kamenice 5, A26, 625 00 BRNO, Czech Republic; 38Max Planck Institute for Dynamics of Complex Technical Systems, Sandtorstrasse
1, 39106 Magdeburg, Germany; 39Department of Biomolecular Sciences, Max Planck Institute of Colloids and Interfaces, 14424
Potsdam, Germany; 40AstraZeneca, Granta Park, Cambridgeshire, CB21 6GH United Kingdom; 41Merck, 2015 Galloping Hill Rd, Kenilworth,
New Jersey 07033; 42Analytical R&D, MilliporeSigma, 2909 Laclede Ave. St. Louis, Missouri 63103; 43MS Bioworks, LLC, 3950 Varsity Drive
Ann Arbor, Michigan 48108; 44MSD, Molenstraat 110, 5342 CC Oss, The Netherlands; 45Exploratory Research Center on Life and Living
Systems (ExCELLS), National Institutes of Natural Sciences, 5â1 Higashiyama, Myodaiji, Okazaki 444â8787 Japan; 46Graduate School of
Pharmaceutical Sciences, Nagoya City University, 3â1 Tanabe-dori, Mizuhoku, Nagoya 467â8603 Japan; 47Medical & Biological Laboratories
Co., Ltd, 2-22-8 Chikusa, Chikusa-ku, Nagoya 464â0858 Japan; 48National Institute for Biological Standards and Control, Blanche Lane, South
Mimms, Potters Bar, Hertfordshire EN6 3QG United Kingdom; 49Division of Biological Chemistry & Biologicals, National Institute of Health
Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158â8501 Japan; 50New England Biolabs, Inc., 240 County Road, Ipswich, Massachusetts
01938; 51New York University, 100 Washington Square East New York City, New York 10003; 52Target Discovery Institute, Nuffield Department
of Medicine, University of Oxford, Roosevelt Drive, Oxford, OX3 7FZ, United Kingdom; 53GlycoScience Group, The National Institute for
Bioprocessing Research and Training, Fosters Avenue, Mount Merrion, Blackrock, Co. Dublin, Ireland; 54Department of Chemistry, North
Carolina State University, 2620 Yarborough Drive Raleigh, North Carolina 27695; 55Pantheon, 201 College Road East Princeton, New Jersey
08540; 56Pfizer Inc., 1 Burtt Road Andover, Massachusetts 01810; 57Proteodynamics, ZI La Varenne 20â22 rue Henri et Gilberte Goudier 63200
RIOM, France; 58ProZyme, Inc., 3832 Bay Center Place Hayward, California 94545; 59Koichi Tanaka Mass Spectrometry Research Laboratory,
Shimadzu Corporation, 1 Nishinokyo Kuwabara-cho Nakagyo-ku, Kyoto, 604 8511 Japan; 60Childrenâs GMP LLC, St. Jude Childrenâs
Research Hospital, 262 Danny Thomas Place Memphis, Tennessee 38105; 61Sumitomo Bakelite Co., Ltd., 1â5 Muromati 1-Chome, Nishiku,
Kobe, 651â2241 Japan; 62Synthon Biopharmaceuticals, Microweg 22 P.O. Box 7071, 6503 GN Nijmegen, The Netherlands; 63Takeda
Pharmaceuticals International Co., 40 Landsdowne Street Cambridge, Massachusetts 02139; 64Department of Chemistry and Biochemistry,
Texas Tech University, 2500 Broadway, Lubbock, Texas 79409; 65Thermo Fisher Scientific, 1214 Oakmead Parkway Sunnyvale, California
94085; 66United States Pharmacopeia India Pvt. Ltd. IKP Knowledge Park, Genome Valley, Shamirpet, Turkapally Village, Medchal District,
Hyderabad 500 101 Telangana, India; 67Alberta Glycomics Centre, University of Alberta, Edmonton, Alberta T6G 2G2 Canada; 68Department
of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2 Canada; 69Department of Chemistry, University of California, One Shields Ave,
Davis, California 95616; 70HorvaÂŽ th Csaba Memorial Laboratory for Bioseparation Sciences, Research Center for Molecular Medicine, Doctoral
School of Molecular Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Egyetem ter 1, Hungary; 71Translational Glycomics
Research Group, Research Institute of Biomolecular and Chemical Engineering, University of Pannonia, Veszprem, Egyetem ut 10, Hungary;
72Delaware Biotechnology Institute, University of Delaware, 15 Innovation Way Newark, Delaware 19711; 73Proteomics Core Facility, University
of Gothenburg, Medicinaregatan 1G SE 41390 Gothenburg, Sweden; 74Department of Medical Biochemistry and Cell Biology, University of
Gothenburg, Institute of Biomedicine, Sahlgrenska Academy, Medicinaregatan 9A, Box 440, 405 30, Gothenburg, Sweden; 75Department of
Clinical Chemistry and Transfusion Medicine, Sahlgrenska Academy at the University of Gothenburg, Bruna Straket 16, 41345 Gothenburg,
Sweden; 76Department of Chemistry, University of Hamburg, Martin Luther King Pl. 6 20146 Hamburg, Germany; 77Department of Chemistry,
University of Manitoba, 144 Dysart Road, Winnipeg, Manitoba, Canada R3T 2N2; 78Laboratory of Mass Spectrometry of Interactions and
Systems, University of Strasbourg, UMR Unistra-CNRS 7140, France; 79Natural and Medical Sciences Institute, University of Tuš bingen,
Markwiesenstrae 55, 72770 Reutlingen, Germany; 80Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical
Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands; 81Division of Bioanalytical Chemistry, Amsterdam Institute for
Molecules, Medicines and Systems, Vrije Universiteit Amsterdam, de Boelelaan 1085, 1081 HV Amsterdam, The Netherlands; 82Department
of Chemistry, Waters Corporation, 34 Maple Street Milford, Massachusetts 01757; 83Zoetis, 333 Portage St. Kalamazoo, Michigan 49007
Authorâs ChoiceâFinal version open access under the terms of the Creative Commons CC-BY license.
Received July 24, 2019, and in revised form, August 26, 2019
Published, MCP Papers in Press, October 7, 2019, DOI 10.1074/mcp.RA119.001677
ER: NISTmAb Glycosylation Interlaboratory Study
12 Molecular & Cellular Proteomics 19.1
Downloaded from https://www.mcponline.org by guest on January 20, 2020
ted a total of 103 reports on glycan distributions. The
principal objective of this study was to report and compare
results for the full range of analytical methods presently
used in the glycosylation analysis of mAbs. Therefore,
participation was unrestricted, with laboratories
choosing their own measurement techniques. Protein glycosylation
was determined in various ways, including at
the level of intact mAb, protein fragments, glycopeptides,
or released glycans, using a wide variety of methods for
derivatization, separation, identification, and quantification.
Consequently, the diversity of results was enormous,
with the number of glycan compositions identified by
each laboratory ranging from 4 to 48. In total, one hundred
sixteen glycan compositions were reported, of which 57
compositions could be assigned consensus abundance
values. These consensus medians provide communityderived
values for NISTmAb PS. Agreement with the consensus
medians did not depend on the specific method or
laboratory type. The study provides a view of the current
state-of-the-art for biologic glycosylation measurement
and suggests a clear need for harmonization of glycosylation
analysis methods. Molecular & Cellular Proteomics
19: 11â30, 2020. DOI: 10.1074/mcp.RA119.001677.L
Caractérisation de protéines thérapeutiques par électrophorÚse capillaire (CE) couplée à la spectrométrie de masse (MS)
Monoclonal antibodies (mAbs) are highly complex glycoproteins having a lot of micro-heterogeneities which can influence their effectiveness. As a consequence, it is necessary to develop robust analytical methods, sensitive and specific to characterize them with high accuracy. The purpose of this thesis was to develop analytical methods allowing the multi-level characterization of monoclonal antibody (cetuximab), and antibody drug conjugates (brentuximab vedotin), using on-online or off-line capillary electrophoresis â mass spectrometry coupling. In the first section, a middle-up proteomic approach of cetuximab was carried out using Off-line CZE-UV/MALDI-MS coupling to separate and to characterize Fc/2 and F(ab)â2 charge variants. A top-down characterization of Fc/2 fragments was also employed. Then a new strategy off-line CZE-UV/nanoESI-MS was used to allow the characterization of this partially digest mAbs. Finally, an online coupling by CESI-MS was developed to allow the fast and accurate analysis of middle-up cetuximab. In a second part, the combination of intact, middle-up and bottom-up proteomic carried out on CZE-UV/nanoESI-MS and CESI coupling allowed the most exhaustive characterization of brentuximab vedotin. This methodology allowed the analyze of DAR, the identification of fragments drug conjugates, the simultaneous characterization of the complete structure of antibody, a significant number of post-translational modifications, all peptides drug conjugates and the identification of diagnostic ions.Les anticorps monoclonaux (mAbs) sont des glycoprotĂ©ines complexes possĂ©dant de nombreuses micro-hĂ©tĂ©rogĂ©nĂ©itĂ©s qui peuvent influencer leur efficacitĂ© dans lâorganisme. Il est par consĂ©quent nĂ©cessaire de dĂ©velopper des mĂ©thodes analytiques robustes, sensibles et spĂ©cifiques pour les caractĂ©riser avec la plus grande prĂ©cision. Lâobjectif de cette thĂšse a Ă©tĂ© de dĂ©velopper des mĂ©thodes analytiques permettant la caractĂ©risation fine et Ă diffĂ©rents niveaux dâun anticorps monoclonal, le cetuximab, ainsi quâun anticorps monoclonal conjuguĂ©s Ă un principe actif, le brentuximab vedotin, sur des couplages direct ou indirect de lâĂ©lectrophorĂšse capillaire et la spectromĂ©trie de masse. Dans une premiĂšre partie, une approche middle-up protĂ©omique du cetuximab a Ă©tĂ© rĂ©alisĂ© sur le couplage indirect CZE-UV/MALDI-MS afin de sĂ©parer et caractĂ©riser les variants de charges du fragment F/2 et F(ab)â2 ainsi que la caractĂ©risation top-down des fragments Fc/2. Ensuite une nouvelle stratĂ©gie indirecte CZE-UV/nanoESI-MS a Ă©tĂ© dĂ©veloppĂ©e pour permettre la caractĂ©risation fine de ce mAbs partiellement digĂ©rĂ©. Enfin un couplage direct par CESI-MS a Ă©tĂ© dĂ©veloppĂ© pour permettre lâanalyse rapide et prĂ©cise du cetuximab middle-up. Dans une deuxiĂšme partie, la combinaison dâanalyse de mAbs dâintact, middle-up et bottom-up protĂ©omique a Ă©tĂ© rĂ©alisĂ©e sur le couplage CZE-UV/nanoESI-MS et CESI-MS. Cela a permis la caractĂ©risation Ă diffĂ©rent niveau du brentuximab vedotin. Cette mĂ©thodologie a permis lâanalyse du DAR, lâidentification de fragments conjuguĂ©s, la caractĂ©risation simultanĂ©e de la sĂ©quence complĂšte de lâanticorps, dâun grand nombre de modifications post-traductionnelles, la caractĂ©risation des peptides conjuguĂ©s ainsi que lâidentification dâions diagnostiques du principe actif
Characterization of cetuximab Fc/2 dimers by off-line CZE-MS
Monoclonal antibody (mAb) therapeutics attract the largest concern due to their strong therapeutic potency and specificity. The Fc region of mAbs is common to many new biotherapeutics as biosimilar, antibody drug conjugate or fusion protein. Fc region has consequences for Fc-mediated effector functions that might be desirable for therapeutic applications. As a consequence, there is a continuous need for improvement of analytical methods to enable fast and accurate characterization of biotherapeutics. Capillary zone electrophoresis-Mass spectrometry couplings (CZE-MS) appear really attractive methods for the characterization of biological samples. In this report, we used CZE-MS systems developed in house and native MS infusion to allow precise middle-up characterization of Fc/2 variant of cetuximab. Molecular weights were measured for three Fc/2 charge variants detected in the CZE separation of cetuximab subunits. Two Fc/2 C-terminal lysine variants were identified and separated. As the aim is to understand the presence of three peaks in the CZE separation for two Fc/2 subunits, we developed a strategy using CZE-UV/MALDI-MS and CZE-UV/ESI-MS to evaluate the role of N-glycosylation and C-terminal lysine truncation on the CZE separation. The chemical structure of N-glycosylation expressed on the Fc region of cetuximab does not influence CZE separation while C-terminal lysine is significantly influencing separation. In addition, native MS infusion demonstrated the characterization of Fc/2 dimers at pH 5.7 and 6.8 and the first separation of these aggregates using CZE-MS
Glycoform Separation and Characterization of Cetuximab Variants by Middle-up Off-Line Capillary Zone Electrophoresis-UV/Electrospray Ionization-MS
Monoclonal
antibodies (mAbs) are highly complex glycoproteins that present a
wide range of microheterogeneities that requires multiple analytical
methods for full structure assessment and quality control. Capillary
zone electrophoresis-mass spectrometry (CZE-MS) couplings, especially
by electrospray ionization (ESI), appear to be really attractive methods
for the characterization of biological samples. However, due to the
presence of non- or medium volatile salts in the background electrolyte
(BGE), online CZE-ESI-MS coupling is difficult to implement for mAbs
isoforms separation. Here, we report an original strategy to perform
off-line CZE-ESI-MS using CZE-UV/fraction collection technology to
perform CZE separation, followed by ESI-MS infusion of the different
fractions using the capillary electrophoresis-electrospray ionization
(CESI) interface as the nanoESI infusion platform. As the aim is to
conserve electrophoretic resolution and complete compatibility with
ESI-MS without sample treatment, hydroxypropylcellulose (HPC) coated
capillary was used to prevent analyte adsorption and asymmetric CZE
conditions involving different BGE at both ends of the capillary have
been developed. The efficiency of our strategy was validated with
the separation of Cetuximab charge variant by the middle-up approach.
Molecular weights were measured for six charge variants detected in
the CZE separation of Cetuximab subunits. The first three peaks correspond
to Fc/2 variants with electrophoretic resolution up to 2.10, and the
last three peaks correspond to FÂ(abâČ)<sub>2</sub> variants
with average electrophoretic resolution of 1.05. Two Fc/2 C-terminal
lysine variants were identified and separated. Moreover, separation
of Fc/2 fragments allowed the glycoprofiling of the variants with
the characterization of 7 different glycoforms. Regarding the FÂ(abâČ)<sub>2</sub> domain, 8 glycoforms were detected and separated in three
different peaks following the presence of N-glycolyl neuraminic acid
residues in some glycan structures. This work highlights the potential
of CZE technology to perform separation of mAbs especially when they
carry sialic acid carbohydrates